HORSHOLM, Denmark--(BUSINESS WIRE)--LifeCycle Pharma A/S (OMX: LCP) (the “Company” or “LCP”), an emerging specialty pharmaceutical company, today announced that it has signed a collaboration Agreement with a Top 10 pharmaceutical company (“pharma company”). Per the terms of the agreement, the pharma company will use LCP’s MeltDose® technology to conduct a preclinical feasibility study in order to investigate a new formulation of one of its product candidates. No financial terms were disclosed.
